Renin angiotensin system genes are biomarkers for personalized treatment of acute myeloid leukemia with Doxorubicin as well as etoposide

• DOI: 10.1371/journal.pone.0242497
• Publication Date: 2020-11-25T18:24:34Z
• Authors: Seyhan Turk; Can Turk; Muhammad Waqas Akbar; Baris Kucukkaraduman; Murat Isbilen; Secil Demirkol Canli; Umit Yavuz Malkan; Mufide Okay; Gulberk Ucar; Nilgun Sayinalp; Ibrahim Celaletti...; Ali Osmay Gure
• Keywords: NPM1

Despite the availability of various treatment protocols, response to therapy in patients with Acute Myeloid Leukemia (AML) remains largely unpredictable. Transcriptomic profiling studies have thus far revealed presence molecular subtypes AML that are not accounted for by standard clinical parameters or routinely used biomarkers. Such predicted vary chemotherapy targeted therapy. The Renin-Angiotensin System (RAS) is an important group proteins play a critical role regulating blood pressure, vascular resistance and fluid/electrolyte balance. RAS pathway genes also known be present locally tissues such as bone marrow, where they leukemic hematopoiesis. In this study, we asked if could utilized predict drug responses AML. We show combined silico analysis up five can reliably sensitivity Doxorubicin well Etoposide same when tested vitro . Additionally, gene set enrichment TNF-alpha type-I IFN among sensitive, TGF-beta fibronectin related resistant cancer cells. However, does seem reflect epithelial mesenchymal transition per se. identified stratify into distinct prognosis. Together, our results demonstrate biomarkers prognostication